Corporate Presentation - June 2019 Symbol: CVSI

CBD-BASEDCONSUMER PRODUCTS& PHARMACEUTICALS

2

This presentation may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks and uncertainties.

This Overview does not constitute an offer to sell or a solicitation of an offer to buy any securities of CV Sciences, Inc. The company is not soliciting any investment from this presentation or event attendees. Offers to sell or solicitations of offers to buy securities of the company will be made pursuant to the registration requirements of the Securities Act of 1933, or regulations of the Securities and Exchange Commission, and under relevant state securities laws; or in accordance with lawful exemptions from registration requirements under applicable federal and state securities laws and regulations.

SAFE HARBOR & DISCLAIMER

3

CV SCIENCES – WHO WE ARE

▪ OTCQB: CVSI

▪ ~$400M market cap

▪ Top selling hemp-derived CBD brand in the natural product industry

▪ Two operating divisions: 1. Consumer products2. Drug development

4

DIFFERENTIATED PRODUCT PORTFOLIO

Health & Wellness Products

▪ 50+ SKUs

▪ Focus on Nutritional Supplements & Topicals

▪ First Hemp-based CBD company to complete the GRAS self-affirmation process

*Per SPINS in the natural products channel. SPINS is the leading provider of analytics reportingfor the Natural, Organic and Specialty Products Industry.

5

13 products in development for 2019

AGGRESSIVE INNOVATION PIPELINE

9 new products already in market this year

6

Business Model – Focus on Highest, Value-Added Areas▪ Increase distribution with efficient sales and market model▪ Focus on quality and innovative products▪ Lead and own the science▪ Educate consumers

Supply Chain – Flexible, Asset Light, Capital Efficient ▪ We outsource high-CAPEX fixed investments▪ Focused on refining the highest quality, hemp-based CBD without investment in farming,

cultivation, extraction or multiple vertical product line production facilities▪ Leveraging in-house refining expertise, new product R&D and QA/QC

Primary Operations in San Diego ▪ Approximately 33,000 square feet under roof▪ Includes Sales, Marketing, Warehouse/Fulfillment and all other Operations▪ Current supply-chain capacity is sufficient to support 2019/2020 sales forecast▪ Supply-Chain capacity expansion plans are in progress

OPERATING STRATEGY

7

Joseph Dowling, Chief Executive Officer▪ 35 years of experience in leadership positions with focused expertise in operations, finance, and business and corporate development. ▪ Previously President and Chief Financial Officer of MediVas, LLC, a biotechnology company focused on drug formulation and delivery including

license agreements with Pfizer, Merck, Wyeth, DSM, Guidant and Boston Scientific. ▪ Served as a Managing Director at Citigroup, and also held various operating, finance and accounting roles in public accounting and in banking. Joerg Grasser, Chief Financial Officer▪ 20+ years of experience and an extensive background in accounting, finance, financial reporting and operations.▪ Formerly Controller at Ballast Point Brewing, a subsidiary of Constellation Brands, Inc. and held senior finance positions with Sequenom, Inc and

Peregrine Semiconductor Corporation.▪ Began his career at KPMG LLP providing audit and IT advisory services, advancing to senior audit manager. Dr. Douglas “Duffy” MacKay, Senior Vice President, Science and Regulatory Affairs▪ Ten-year career with the Council for Responsible Nutrition (CRN) where he served as the senior vice president, scientific and regulatory affairs. ▪ At CRN, Dr. MacKay led successful policy initiatives including launching an industry-wide self-regulatory product registry which influenced FDA’s

current commitment to developing an FDA mandatory product registry. ▪ Spent ten years in private practice, while also working as a medical and nutrition expert for two dietary supplement companies, including four

years as an executive with Nordic Naturals. Dr. MacKay serves on the Advisory Board for the American Botanical Council and the NSF Task Force on hemp-derived products.

Stuart Tomc, Senior Vice President Business Development▪ A recognized authority on dietary supplements, with 20+ years of experience in the nutritional health industry. ▪ Formerly Vice President of North American Herb and Spice for 10 years.▪ Served as Global Educator for omega-3 market leader, Nordic Naturals.▪ A renowned educator known for his print interviews and contributions to noted books on integrative medicine, as well as his 4000 radio

appearances. Michael Mona, III, Chief Operating Officer▪ Co-founder of CV Sciences with nearly a decade of hemp-based, supply chain expertise, including farming, cultivation, extraction, oil processing,

manufacturing, quality control, warehousing, shipping and fulfillment. ▪ Spearheaded growth of Company’s industry-leading consumer products brand, PlusCBD Oil, the #1 selling hemp CBD brand in the natural

products channel. ▪ Hemp industry leadership led to the founding of the US Hemp Roundtable, a trade coalition focused on lobbying efforts towards positive hemp

legislation and standardization of a properly regulated supply chain process. Karen Moyer, Vice President Marketing▪ 30-year career in brand marketing and innovation, most recently as VP of Marketing for disruptive brands GoMacro bars and Arctic Zero ice

cream. ▪ Proven track-record scaling businesses with a command of digital advertising, social media, shopper marketing, brand positioning and

consumer research. ▪ Served as Director of Brand Management and Communications for Petco’s private brands. ▪ 22 years at Kashi Company leading brand strategy, advertising and managing profitability across cereals and snacks.

STRONG MANAGEMENT TEAM

8

QUALITY-FOCUSED SUPPLY CHAIN

HARVEST EXTRACT REFINE & FORMULATE MANUFACTURE DISTRIBUTE

QA/QC FROM SEED TO SHELF

outsourced outsourced outsourced

9

SALES MODEL − DRIVES NATIONAL DISTRIBUTION

30+ Internal Sales Staff

10

SALES MODEL − DRIVES NATIONAL DISTRIBUTION

Leverage Hundreds of Brokers

11

SALES MODEL − DRIVES NATIONAL AVAILABILITY

Result − National Distribution in Thousands of Retail Outlets

12

RAPIDLY GROWING RETAIL DISTRIBUTION3400

3200

3000

2800

2600

2400

2200

2000

1800

1600

1400

1200

1000

800

600

400

200

0MARCH2015

JUNE2015

SEPT2015

DEC2015

MARCH2016

JUNE2016

SEPT2016

DEC2016

MARCH2017

JUNE2017

SEPT2017

DEC2017

MARCH2018

JUNE2018

SEPT2018

DEC2018

MARCH2019

STORE COUNT AS OFMARCH 31, 2019

3,300+ 2018 FARM BILL PASSED

1

PlusCBD™ Oil Roll-OnsLaunch at 945 Kroger Stores

in 17 U.S. States

KROGER LAUNCH

14

RAPIDLY GROWING RETAIL DISTRIBUTION4600

4400

4200

4000

3800

3600

3400

3200

3000

2800

2600

2400

2200

2000

1800

1600

1400

1200

1000

800

600

400

200

0MARCH2015

JUNE2015

SEPT2015

DEC2015

MARCH2016

JUNE2016

SEPT2016

DEC2016

MARCH2017

JUNE2017

SEPT2017

DEC2017

MARCH2018

JUNE2018

SEPT2018

DEC2018

MARCH2019

STORE COUNT AS OFJUNE 12, 2019

4,5912018 FARM

BILL PASSED

JUNE2019

15

$11

$21

$48

$8

$15

$0

$20

$40

$60

2016 2017 2018 Q1:18 Q1:19

$7

$15

$34

$6

$11

55%

60%

65%

70%

75%

$0

$10

$20

$30

$40

2016 2017 2018 Q1:18 Q1:19

Gross Profit Gross Margin

GROWTH & STRONG MARGIN PROFILE

REVENUE GROSS PROFIT & MARGIN

Revenuein millions

Gross Profitin millions

Gross Margin %

16

COMPREHENSIVE MARKETING STRATEGIES

GROW PENETRATION IN THE RIGHT HOUSEHOLDS

EDUCATE AND INFLUENCE TO DRIVE TRIAL

DOMINATE SHARE OF VOICE

17

BIG UPSIDE – BROAD CONSUMER TARGET & NEED STATES

39%47%

31%

16%

61%53%

69%

84%

Gen Z Millennial Gen X Boomer

Yes No

PURCHASED CBD IN THE PAST 12 MONTHS

REASONS FOR USE OF CBD

*Source: Nutrition Business Journal Hemp & CBD Guide 2019

44%

36%

34%

29%

25%

25%

21%

20%

14%

11%

Anxiety

Pain

General relaxation

Sleeplessness

Depression

General well-being

Arthritis

Inflammation

Illness prevention

Other

18

“Wow! I am in love with the

whole line of CBD.... My

skin feels amazing and I feel great!!!!”

“This stuff actually works. It's not some stupid magic fairy dust. I did a heavy work out (weight training) and often, after a few hours, I dive into a bottle of ibuprofen. But this time I took a couple of droppers full of CBD oil. It worked. The pain was gone.”

Live on the +Plus Side™

PLUSCBD OIL PRODUCTS CHANGE LIVES

19

ROBUST TRADE MARKETING & EDUCATION PLANS

▪ 40+ trade shows annually

▪ Advisor-led webinars

▪ Infield education, retailer trainings, store events

▪ Expert Voice online retail training portal

▪ Demos

▪ Co-op advertising

20

OUTDOOR MAGAZINE

MONTHLY FLYER NEWSPAPER

CO-OP ADVERTISING HIGHLIGHTS

21

CO-OP ADVERTISING HIGHLIGHTS

OUTDOOR MAGAZINE

22

▪ Digital advertising, email marketing and affiliate programs

▪ Social media and influencer marketing

▪ Shopper marketing

▪ Consumer events and sampling programs

▪ iHeartRadio, national health talk radio

▪ Public relations

COMPELLING DIRECT TO CONSUMER MARKETING PLANS

23

INFLUENCERS SPREAD THE WORD

24

THE LATEST BUZZ ON PLUSCBD OIL

25

THE LATEST BUZZ ON PLUSCBD OIL

26

CV SCIENCES IN THE NEWS

27

CV SCIENCES IN THE NEWS

28

THE FUTURE OF CANNABIS REGULATION

Pharma

Dispensaries

THREE SWIM LANES

Agricultural Certified Food and Fiber HempExtracts

Pharmaceutical Drugs CBD Isolates or Synthetic

Retail

Botanical Cannabis ExtractsRecreational and Medicinal

29

DRUGDEVELOPMENTDIVISION

30

Overview

▪ CBD and nicotine combination

▪ Medical indication – smokeless tobacco cessation

▪ Proprietary technology (patent pending)

▪ No current treatment – huge unmet need

NICOTINE CANNABIDIOL

+

DRUG DEVELOPMENT PROGRAM

31

Source: Euromonitor International, National Survey on Drug Use and Health Centers for Disease Control and Prevention

20%

10%

0%

-10%

-20%

-30%

-40%

2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

CU

MU

LATI

VE C

HA

NG

E IN

U.S

. UN

IT S

ALE

S

SMOKELESS TOBACCO250,000 deaths/year

CIGARETTES6,000,000 deaths/year

TOBACCO USE TRENDS

32

No current FDA-approved drugs to treat smokeless tobacco use and addiction.

▪ There are only 2 smoking cessation FDA-approved drugs – Chantix (Pfizer) and Zyban (GSK)

▪ Until recently, both Chantix and Zyban had “black box warnings” that call attention to serious or life-threatening risks in taking these approved products.

2022

Estimated Smokeless TobaccoTreatment Market

$4 Billion

MARKET POTENTIAL

33

▪ Engaged with the FDA

▪ Complete nonclinical toxicology studies in 2019

▪ Submit Investigational New Drug (IND) application in late 2019/early 2020

▪ Begin clinical trials in 2019

DRUG DEVELOPMENT TIMELINE

34

APPENDIX

35

▪ Regulatory clarity

▪ Opens Food, Drug & Mass channels▪ CV Sciences shipped its first order to a leading national

drug store chain in late Q1:2019

▪ Catalyst for significantly expanded market opportunity▪ Market predictions differ, but assume significant growth

2018 FARM BILL – EXPANDS MARKET OPPORTUNITY

$12 BillionWith potential to achieve $31 - $46 billion

$16 Billion$22 Billion

36

THE PATH FORWARD IS FOOD/FIBER TYPE HEMP

37

• 2018 Farm Bill – Hemp defined as Cannabis sativa L. (below 0.3% THC) is erroneously being discussed as a catch-all phrase

• USDA may require specific seed varieties to be registered as varieties of ‘agricultural hemp’ plants vs. drug varieties

• There is no indication that FDA will extend the Farm Bill definition of Hemp to finished dietary supplement or food products

THE PATH FORWARD IS FOOD/FIBER TYPE HEMP

38

0.3% THC IS ONLY ONE SMALL DIFFERENCE

HEMP AND MARIJUANA COMPARED

39

HEMPAgricultural Commodity

MARIJUANAControlled Substance

Constituents Include• THC• CBD• Other Cannabinoids

0.3% THCUSDA regulations

Hemp Food/Supplement/Cosmetic

Legal Hemp Products

State-Based RecreationalAnd Medical

Industries

Prescription Drugs

CANNABIS SATIVA L.

40

41

State regulated recreational marijuana• Full range of THC/CBD products,

outside of FDA jurisdiction • Limited to intra-state commerce

FDA regulated hemp products• Food - hulled hemp seed, hemp seed protein powder,

and hemp seed oil – no isolated CBD• Dietary Supplements – USDA registered food/fiber

hemp extracts with NDINs – no isolated CBD• Cosmetics – FDA compliant ingredients meeting

cosmetic safety standard

FDA regulated prescription drugs• Epidiolex and more

THREE DISTINCT CANNABIS PRODUCT CATEGORIES

THE FUTURE